WASHINGTON—The Federal Trade Commission on Tuesday challenged Illumina Inc.’s. proposed acquisition of Pacific Biosciences of California, a $1.2 billion deal in the life-sciences industry.
The FTC is bringing an administrative lawsuit alleging the biotech acquisition would allow Illumina to unlawfully maintain a monopoly in next-generation DNA sequencing by eliminating PacBio as a nascent competitor.
المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
Digital banking app MoneyLion is launching stock-trading in 2020 - Business InsiderMoneyLion, an online lending startup that raised over $200 million touting itself as an affordable banking option, is adding stock-trading in 2020
اقرأ أكثر »
DuPont chairman says deal with IFF gives new company 'double the R&D' of competitorsInternational Flavors & Fragrances is merging with DuPont's nutrition and biosciences unit, creating a $45.4 billion consumer goods giant. when do these CEO's lose their jobs for stocks which under perform greatly? $IFF stock been awful in a huge stock market year. Accountability is needed.
اقرأ أكثر »